Sino Biopharmaceutical Limited (01177) announced on July 15, 2025, that its wholly-owned subsidiary, Zhengda Pharmaceutical Investment (Beijing) Group Co., Ltd., will acquire a 95.09% equity interest in LaNova Medicines. The transaction carries a maximum consideration of approximately US$951 million. After deducting LaNova's estimated cash and bank deposits of US$450 million at closing, the net payment required from the buyer amounts to roughly US$501 million.
Currently, the acquiring subsidiary holds a 4.91% stake in LaNova Medicines. Upon completion of the acquisition, Sino Biopharmaceutical will own 100% of LaNova, making it an indirect wholly-owned subsidiary.
LaNova Medicines represents a globally leading innovative drug R&D company specializing in tumor immunology and tumor microenvironment research. This strategic move substantially aligns with Sino Biopharmaceutical's innovation-driven and internationalization strategy. The acquisition is expected to significantly enhance the group's core competitiveness and global influence within the oncology innovation sector.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.